NovoStent raises $3m for anchored helical stent human trial:
This article was originally published in Clinica
Executive Summary
NovoStent has raised an additional $3.1m in a second round of financing. The proceeds will be used to develop "more robust human data" on its proprietary "anchored" helical stent technology, which the Mountain View, California firm claims to offer better durability, flexibility and compression resistance than standard stent designs. The first human trial on NovoStent's device, involving the superficial femoral artery, is slated to start in 2006.